Roche And Recursion’s AI Drug Discovery Pact To Focus On Neuroscience
Another Boost For AI
The 10-year deal aims to use artificial intelligence to map out the cellular biology behind neuroscience and oncology and accelerate drug discovery in another boost to the field.
You may also be interested in...
Barbara Lueckel, head of research technologies partnering, said Roche’s approach to platform deals has evolved with a focus on “generational technologies” to answer tough scientific questions.
Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.
Financing Snapshot: The AI/ML-focused company raised $101m in a series A round and plans to use the funding to develop immunoglobulin- and cell-mediated autoimmune disorder drugs.